Start-Up Previews (2/02)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Small Size=Big Potential , features profiles of C Sixty Inc., engeneOS Inc., Nanospectra Biosciences Inc. and Oxonica Ltd., Plus these Selected Start-Ups across Health Care: Addiction Therapies Inc., ImpactRx Inc., Ingenium Pharmaceuticals AG and Insulet Corp.
You may also be interested in...
Wave’s Duchenne muscular dystrophy drug and Lilly’s chronic pain R&D will test the agency’s CID meeting pilot program, while FDA issues draft guidance that highlights potential uses for complex innovative trial designs.
Agency officials can now discuss the ideas that have been accepted, though not in great detail.
FDA requests immediate removal of ranitidine OTC and Rx drugs after third-party testing finds contaminant NDMA increases during storage, especially at higher temperatures. CDER Director Janet Woodcock asks firms to reformulate products to be stable as the ingredient remains approved.